tiprankstipranks
Trending News
More News >
Biohaven Ltd. (BHVN)
NYSE:BHVN
US Market

Biohaven Ltd. (BHVN) Stock Forecast & Price Target

Compare
844 Followers
See the Price Targets and Ratings of:

BHVN Analyst Ratings

Moderate Buy
11Ratings
Moderate Buy
7 Buy
4 Hold
0 Sell
Based on 11 analysts giving stock ratings to
Biohaven
Ltd.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BHVN Stock 12 Month Forecast

Average Price Target

$17.33
▲(54.32% Upside)
Based on 11 Wall Street analysts offering 12 month price targets for Biohaven Ltd. in the last 3 months. The average price target is $17.33 with a high forecast of $30.00 and a low forecast of $11.00. The average price target represents a 54.32% change from the last price of $11.23.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","39":"$39","15.75":"$15.75","23.5":"$23.5","31.25":"$31.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$11.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,15.75,23.5,31.25,39],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.75,13.153846153846153,14.557692307692307,15.961538461538462,17.365384615384613,18.769230769230766,20.173076923076923,21.576923076923077,22.98076923076923,24.384615384615383,25.788461538461537,27.192307692307693,28.596153846153847,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.75,12.179230769230768,12.608461538461539,13.037692307692307,13.466923076923077,13.896153846153846,14.325384615384614,14.754615384615384,15.183846153846153,15.613076923076921,16.04230769230769,16.471538461538458,16.900769230769228,{"y":17.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.75,11.692307692307692,11.634615384615385,11.576923076923077,11.51923076923077,11.461538461538462,11.403846153846153,11.346153846153847,11.288461538461538,11.23076923076923,11.173076923076923,11.115384615384615,11.057692307692308,{"y":11,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":38.25,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.18,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.6,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.68,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.96,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.71,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.89,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.82,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.32,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.29,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.75,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$30.00Average Price Target$17.33Lowest Price Target$11.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on BHVN
Piper Sandler
Piper Sandler
$30
Buy
167.14%
Upside
Reiterated
02/23/26
Analysts Are Bullish on Top Healthcare Stocks: Biohaven Ltd. (BHVN), Oric Pharmaceuticals (ORIC)
Citi
$14
Buy
24.67%
Upside
Reiterated
02/18/26
Analysts Conflicted on These Healthcare Names: Biohaven Ltd. (NYSE: BHVN), Olema Pharmaceuticals (NASDAQ: OLMA) and Hims & Hers Health (NYSE: HIMS)
Goldman Sachs Analyst forecast on BHVN
Goldman Sachs
Goldman Sachs
$23
Buy
104.81%
Upside
Initiated
02/05/26
Analysts Offer Insights on Healthcare Companies: Biogen (NASDAQ: BIIB), Biohaven Ltd. (NYSE: BHVN) and Adaptive Biotechnologies (NASDAQ: ADPT)
RBC Capital Analyst forecast on BHVN
RBC Capital
RBC Capital
$9$22
Buy
95.90%
Upside
Upgraded
01/21/26
Biohaven upgraded to Outperform from Sector Perform at RBC CapitalBiohaven upgraded to Outperform from Sector Perform at RBC Capital
William Blair Analyst forecast on BHVN
William Blair
William Blair
Hold
Reiterated
01/13/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Alphatec Holdings (NASDAQ: ATEC), Biohaven Ltd. (NYSE: BHVN) and Syndax Pharmaceuticals (NASDAQ: SNDX)
TD Cowen
$50$15
Buy
33.57%
Upside
Reiterated
01/13/26
Bank of America Securities Analyst forecast on BHVN
Bank of America Securities
Bank of America Securities
$10$15
Hold
33.57%
Upside
Reiterated
01/12/26
Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (NASDAQ: DAWN), BridgeBio Pharma (NASDAQ: BBIO) and Biohaven Ltd. (NYSE: BHVN)
H.C. Wainwright Analyst forecast on BHVN
H.C. Wainwright
H.C. Wainwright
$11
Hold
-2.05%
Downside
Reiterated
12/26/25
Analysts Conflicted on These Healthcare Names: Xenon (NASDAQ: XENE) and Biohaven Ltd. (NYSE: BHVN)
J.P. Morgan Analyst forecast on BHVN
J.P. Morgan
J.P. Morgan
Buy
Reiterated
12/26/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: Novavax (NASDAQ: NVAX), Xenon (NASDAQ: XENE) and Biohaven Ltd. (NYSE: BHVN)
Leerink Partners Analyst forecast on BHVN
Leerink Partners
Leerink Partners
$50$15
Buy
33.57%
Upside
Reiterated
12/25/25
Biohaven: MDD Setback but Epilepsy Refocus and Diversified Pipeline Support Continued Buy Rating
UBS
$26$11
Hold
-2.05%
Downside
Downgraded
11/28/25
Cautious Hold Rating on Biohaven Ltd. Amidst R&D Setbacks and Competitive Challenges
Morgan Stanley Analyst forecast on BHVN
Morgan Stanley
Morgan Stanley
$54$26
Buy
131.52%
Upside
Reiterated
11/17/25
Strategic Adjustments and Future Potential: Biohaven Ltd. Receives Buy Rating Amidst Regulatory Challenges
BTIG
$16
Buy
42.48%
Upside
Reiterated
11/17/25
Strategic Positioning and Growth Potential Drive Buy Rating for Biohaven Ltd.
Bernstein
$34$9
Hold
-19.86%
Downside
Downgraded
11/06/25
Hold Rating on Biohaven Ltd. Amid Liquidity Challenges and Uncertain Clinical Outcomes
Raymond James Analyst forecast on BHVN
Raymond James
Raymond James
Buy
Reiterated
11/03/25
Optimistic Buy Rating for Biohaven Ltd. Amidst High-Risk PDUFA Decision on Troriluzole
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on BHVN
Piper Sandler
Piper Sandler
$30
Buy
167.14%
Upside
Reiterated
02/23/26
Analysts Are Bullish on Top Healthcare Stocks: Biohaven Ltd. (BHVN), Oric Pharmaceuticals (ORIC)
Citi
$14
Buy
24.67%
Upside
Reiterated
02/18/26
Analysts Conflicted on These Healthcare Names: Biohaven Ltd. (NYSE: BHVN), Olema Pharmaceuticals (NASDAQ: OLMA) and Hims & Hers Health (NYSE: HIMS)
Goldman Sachs Analyst forecast on BHVN
Goldman Sachs
Goldman Sachs
$23
Buy
104.81%
Upside
Initiated
02/05/26
Analysts Offer Insights on Healthcare Companies: Biogen (NASDAQ: BIIB), Biohaven Ltd. (NYSE: BHVN) and Adaptive Biotechnologies (NASDAQ: ADPT)
RBC Capital Analyst forecast on BHVN
RBC Capital
RBC Capital
$9$22
Buy
95.90%
Upside
Upgraded
01/21/26
Biohaven upgraded to Outperform from Sector Perform at RBC CapitalBiohaven upgraded to Outperform from Sector Perform at RBC Capital
William Blair Analyst forecast on BHVN
William Blair
William Blair
Hold
Reiterated
01/13/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Alphatec Holdings (NASDAQ: ATEC), Biohaven Ltd. (NYSE: BHVN) and Syndax Pharmaceuticals (NASDAQ: SNDX)
TD Cowen
$50$15
Buy
33.57%
Upside
Reiterated
01/13/26
Bank of America Securities Analyst forecast on BHVN
Bank of America Securities
Bank of America Securities
$10$15
Hold
33.57%
Upside
Reiterated
01/12/26
Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (NASDAQ: DAWN), BridgeBio Pharma (NASDAQ: BBIO) and Biohaven Ltd. (NYSE: BHVN)
H.C. Wainwright Analyst forecast on BHVN
H.C. Wainwright
H.C. Wainwright
$11
Hold
-2.05%
Downside
Reiterated
12/26/25
Analysts Conflicted on These Healthcare Names: Xenon (NASDAQ: XENE) and Biohaven Ltd. (NYSE: BHVN)
J.P. Morgan Analyst forecast on BHVN
J.P. Morgan
J.P. Morgan
Buy
Reiterated
12/26/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: Novavax (NASDAQ: NVAX), Xenon (NASDAQ: XENE) and Biohaven Ltd. (NYSE: BHVN)
Leerink Partners Analyst forecast on BHVN
Leerink Partners
Leerink Partners
$50$15
Buy
33.57%
Upside
Reiterated
12/25/25
Biohaven: MDD Setback but Epilepsy Refocus and Diversified Pipeline Support Continued Buy Rating
UBS
$26$11
Hold
-2.05%
Downside
Downgraded
11/28/25
Cautious Hold Rating on Biohaven Ltd. Amidst R&D Setbacks and Competitive Challenges
Morgan Stanley Analyst forecast on BHVN
Morgan Stanley
Morgan Stanley
$54$26
Buy
131.52%
Upside
Reiterated
11/17/25
Strategic Adjustments and Future Potential: Biohaven Ltd. Receives Buy Rating Amidst Regulatory Challenges
BTIG
$16
Buy
42.48%
Upside
Reiterated
11/17/25
Strategic Positioning and Growth Potential Drive Buy Rating for Biohaven Ltd.
Bernstein
$34$9
Hold
-19.86%
Downside
Downgraded
11/06/25
Hold Rating on Biohaven Ltd. Amid Liquidity Challenges and Uncertain Clinical Outcomes
Raymond James Analyst forecast on BHVN
Raymond James
Raymond James
Buy
Reiterated
11/03/25
Optimistic Buy Rating for Biohaven Ltd. Amidst High-Risk PDUFA Decision on Troriluzole
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Biohaven Ltd.

3 Months
xxx
Success Rate
7/14 ratings generated profit
50%
Average Return
+0.46%
a xxx
rating ―
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +0.46% per trade.
1 Year
Success Rate
10/22 ratings generated profit
45%
Average Return
+23.19%
a rating ―
Copying Thomas Shrader's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of +23.19% per trade.
2 Years
xxx
Success Rate
3/12 ratings generated profit
25%
Average Return
-26.72%
a xxx
rating ―
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 25.00% of your transactions generating a profit, with an average return of -26.72% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BHVN Analyst Recommendation Trends

Rating
Oct 25
Nov 25
Dec 25
Jan 26
Feb 26
Strong Buy
16
19
17
16
4
Buy
2
1
4
5
5
Hold
2
8
10
12
5
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
20
28
31
33
14
In the current month, BHVN has received 9 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. BHVN average Analyst price target in the past 3 months is 17.33.
Each month's total comprises the sum of three months' worth of ratings.

BHVN Financial Forecast

BHVN Earnings Forecast

Next quarter’s earnings estimate for BHVN is -$1.19 with a range of -$2.04 to -$0.33. The previous quarter’s EPS was -$1.64. BHVN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year BHVN has Performed in-line its overall industry.
Next quarter’s earnings estimate for BHVN is -$1.19 with a range of -$2.04 to -$0.33. The previous quarter’s EPS was -$1.64. BHVN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year BHVN has Performed in-line its overall industry.
No data currently available

BHVN Sales Forecast

Next quarter’s sales forecast for BHVN is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. BHVN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year BHVN has Performed in-line its overall industry.
Next quarter’s sales forecast for BHVN is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. BHVN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year BHVN has Performed in-line its overall industry.

BHVN Stock Forecast FAQ

What is BHVN’s average 12-month price target, according to analysts?
Based on analyst ratings, Biohaven Ltd.’s 12-month average price target is 17.33.
    What is BHVN’s upside potential, based on the analysts’ average price target?
    Biohaven Ltd. has 54.32% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BHVN a Buy, Sell or Hold?
          Biohaven Ltd. has a consensus rating of Moderate Buy which is based on 7 buy ratings, 4 hold ratings and 0 sell ratings.
            What is Biohaven Ltd.’s price target?
            The average price target for Biohaven Ltd. is 17.33. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $30.00 ,the lowest forecast is $11.00. The average price target represents 54.32% Increase from the current price of $11.23.
              What do analysts say about Biohaven Ltd.?
              Biohaven Ltd.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of BHVN?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.